Cofoe Medical Technology Co Ltd
SZSE:301087
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (4.3), the stock would be worth ¥43.36 (18% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.3 | ¥53.02 |
0%
|
| 3-Year Average | 4.3 | ¥43.36 |
-18%
|
| 5-Year Average | 4.6 | ¥46.36 |
-13%
|
| Industry Average | 8.4 | ¥84.14 |
+59%
|
| Country Average | 13.6 | ¥136.04 |
+157%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Cofoe Medical Technology Co Ltd
SZSE:301087
|
11.1B CNY | 5.3 | 29.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 23.6 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 6.1 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 7.6 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 5.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 6.5 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 9.2 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 5.2 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 17.1 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 5.8 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 8.8 | 20.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8 |
| Median | 13.6 |
| 70th Percentile | 23.3 |
| Max | 17 898 541.1 |
Other Multiples
Cofoe Medical Technology Co Ltd
Glance View
In the vibrant landscape of China's medical device industry, Cofoe Medical Technology Co Ltd emerges as a dynamic player, adeptly navigating the intersection of innovation and practicality. Founded with a mission to enhance healthcare accessibility, the company specializes in the design, production, and distribution of a broad spectrum of medical devices. From blood pressure monitors to thermometers, Cofoe's portfolio is tailored to meet the everyday health monitoring needs of consumers, hospitals, and clinics alike. The firm leverages its extensive research and development capabilities to stay ahead in a rapidly evolving market, ensuring its product offerings are both cutting-edge and user-friendly. Cofoe's business model is intricately woven around capturing value through both scale and precision. The company capitalizes on China's extensive manufacturing capabilities to produce cost-effective yet high-quality medical devices. It maintains a robust supply chain network that ensures efficiency and timely delivery. Moreover, Cofoe channels its marketing efforts through a mix of traditional retail outlets and burgeoning e-commerce platforms, effectively expanding its footprint both domestically and in selected international markets. By focusing on quality control, regulatory compliance, and customer satisfaction, Cofoe reinforces its brand reputation, thereby creating a sustainable competitive advantage and driving revenue growth.